Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Expands By 384.2%

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totaling 20,198 shares, a growth of 384.2% from the August 15th total of 4,171 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 12,801 shares, the days-to-cover ratio is presently 1.6 days.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Pulmatrix in the second quarter valued at approximately $93,000. DRW Securities LLC purchased a new position in Pulmatrix during the fourth quarter worth approximately $46,000. Finally, Dimensional Fund Advisors LP acquired a new position in Pulmatrix during the third quarter worth $52,000. 11.84% of the stock is owned by hedge funds and other institutional investors.

Pulmatrix Trading Down 1.4%

PULM traded down $0.02 on Friday, hitting $1.44. 7,270 shares of the company’s stock were exchanged, compared to its average volume of 29,072. Pulmatrix has a fifty-two week low of $1.16 and a fifty-two week high of $5.50. The stock has a market cap of $5.26 million, a price-to-earnings ratio of -1.31 and a beta of 1.90. The firm has a 50-day moving average price of $1.60 and a 200-day moving average price of $1.61.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($2.00) by $1.71.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Pulmatrix presently has an average rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).